Papers
1
Total Citations
6
H-Index
1
About
Kaixi Zhao is a biopharmaceutical researcher whose work centers on advancing analytical methods for mRNA vaccine quality control, with a particular focus on ensuring the safety and potency of this transformative vaccine platform. Zhao’s most cited study, published in 2024, addresses a critical challenge in mRNA manufacturing: the detection and quantitation of double-stranded RNA (dsRNA) impurities. These byproducts of in vitro transcription can compromise vaccine efficacy and trigger unwanted immune responses. By developing and validating an automated sandwich ELISA assay, Zhao provided a robust, high-throughput tool for the biopharmaceutical industry to monitor dsRNA levels during production. This contribution has already garnered 6 citations in its first year, signaling its importance to the field. Zhao’s work directly supports the scalable, safe manufacture of mRNA vaccines—a technology that has reshaped global public health. For students and researchers in bioprocessing and analytical development, Zhao exemplifies how rigorous assay development can bridge the gap between novel therapeutic platforms and their real-world deployment.
Research Focus
Key Achievements
Top Papers
- 1